Page last updated: 2024-11-04

pantothenic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Pantothenic Acid: A butyryl-beta-alanine that can also be viewed as pantoic acid complexed with BETA ALANINE. It is incorporated into COENZYME A and protects cells against peroxidative damage by increasing the level of GLUTATHIONE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pantothenic acid : A member of the class of pantothenic acids that is an amide formed from pantoic acid and beta-alanine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

vitamin B5 : Any member of a group of vitamers that belong to the chemical structural class called pantothenic acids that exhibit biological activity against vitamin B5 deficiency. Deficiency of vitamin B5 is rare due to its widespread distribution in whole grain cereals, legumes and meat. Symptoms associated with vitamin B5 deficiency are difficult to asses since they are subtle and resemble those of other B vitamin deficiencies. The vitamers include (R)-pantothenic acid and its ionized and salt forms. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

(R)-pantothenate : A pantothenate that is the conjugate base of (R)-pantothenic acid, obtained by deprotonation of the carboxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

(R)-pantothenic acid : A pantothenic acid having R-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6613
CHEMBL ID1594
CHEBI ID46905
SCHEMBL ID5436
MeSH IDM0015824

Synonyms (96)

Synonym
3-(2,4-dihydroxy-3,3-dimethylbutanamido)propanoic acid
vitamin b-5
pantothenic acid [ban]
brn 1727064
n-(2,4-dihydroxy-3,3-dimethylbutyryl)-beta-alanine
kyselina pantothenova [czech]
einecs 201-229-0
PAU ,
pantothenoic acid
chick antidermatitis factor
pantothenic acid, d-
(d)-(+)-pantothenic acid
b-alanine, n-[(2r)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]- (9ci)
beta-alanine, n-[(2r)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]-
(+)-pantothenic acid
(d,+)-n(alpha-gamma-dihydroxy-beta,beta-dimethylbutyryl)-beta-alanine
pantothenic acid, d- (8ci)
hsdb 1020
(r)-n-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-beta-alanine
d(+)-n-(2,4-dihydroxy-3,3-dimethylbutyryl)-beta-alanine
beta-alanine, n-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-, (r)-
d-pantothenic acid
C00864
vitamin b5
(r)-pantothenate
(r)-pantothenic acid
PANTOTHENATE ,
pantothenic acid
79-83-4
n-[(2r)-2,4-dihydroxy-3,3-dimethylbutanoyl]-beta-alanine
DB01783
3-[(2r)-2,4-dihydroxy-3,3-dimethylbutanamido]propanoic acid
d-(+)-pantothenic acid
CHEBI:46905 ,
450B5472-A689-4BCA-9BC1-58691B72D00F
HMS2090P08
3-[[(2r)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoic acid
beta-alanine, n-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-, (r)- (9ci)
BMSE000287
pantothenic acid (ban)
pantothen pharmaselect (tn)
D07413
CHEMBL1594
pantothenic acid (d)
b 5, vitamin
vitamin b 5
b5, vitamin
AKOS016010488
kyselina pantothenova
4-04-00-02569 (beilstein handbook reference)
19f5hk2737 ,
unii-19f5hk2737
NCGC00346610-01
gtpl4668
pantothenic acid [orange book]
pantothenic acid [who-dd]
.beta.-alanine, n-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-, (r)-
pantothenic acid [hsdb]
pantothenic acid [vandf]
vitamin b5 [vandf]
pantothenic acid [inci]
n-((2r)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-.beta.-alanine
vitamin b5 [green book]
pantothenic acid [mart.]
pantothenic acid [mi]
HY-B0430
3-((r)-2,4-dihydroxy-3,3-dimethyl-butyrylamino)-propionic acid
GHOKWGTUZJEAQD-ZETCQYMHSA-N
SCHEMBL5436
n-[(2r)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]-beta-alanine
(r)-3-(2,4-dihydroxy-3,3-dimethylbutanamido)propanoic acid
DTXSID9023417 ,
3-[[(2r)-2,4-dihydroxy-3,3-dimethyl-butanoyl]amino]propionic acid
3-[[(2r)-3,3-dimethyl-2,4-bis(oxidanyl)butanoyl]amino]propanoic acid
HMS3656K08
SBI-0206933.P001
(d)-(+)-pantothenate
delta-pantothenate
d(+)-n-(2,4-dihydroxy-3,3-dimethylbutyryl)-b-alanine
delta-pantothenic acid
SW220291-1
'n-[(2r)-2,4-dihydroxy-3,3-dimethylbutanoyl]-beta-alanine'
Q63390527
(+)-(r)-3-(2,4-dihydroxy-3,3-dimethylbutanamido)propanoic acid
pantothenic-acid
()-pantothenate;()-vitamin b5
AS-75446
n-[(2r)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]-ss-alanine
E83797
EN300-113766
pantothen pharmaselect
pantothenic acid (mart.)
n-((2r)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-beta-alanine
dtxcid203417
beta-alanine, n-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-,(r)-
pantotenico acido

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Idiosyncratic toxic responses are often not detected during this phase in development due to their relative rarity in incidence and differences in species sensitivity."( Metabolic, idiosyncratic toxicity of drugs: overview of the hepatic toxicity induced by the anxiolytic, panadiplon.
Bacon, JA; Brass, EP; Cramer, CT; Petrella, DK; Sun, EL; Ulrich, RG, 2001
)
0.31
"We can conclude from our pilot study that PEDYPHAR ointment may be a promising, safe conservative local treatment."( Safety and efficacy of a new honey ointment on diabetic foot ulcers: a prospective pilot study.
Abdelatif, M; Etmaan, M; Yakoot, M, 2008
)
0.35
" In safety studies, clinical, hematological and bacteriological monitoring of both SIV-positive and SIV-negative Rhesus macaques immunized with ΔleuD ΔpanCD, revealed no vaccine-associated adverse effects."( Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate.
Bloom, BR; Carville, A; Hondalus, MK; Howerth, EW; Magee, DM; Mansfield, KG; Quitugua, T; Sampson, SL, 2011
)
0.37
" Predictivity for adverse outcomes in mammalian prenatal developmental toxicity studies used ToxRefDB and other sources of information, including Stemina Biomarker Discovery's predictive DevTox® model trained on 23 pharmaceutical agents of known developmental toxicity and differing potency."( Identifying developmental toxicity pathways for a subset of ToxCast chemicals using human embryonic stem cells and metabolomics.
Cezar, GG; Conard, KR; Dix, DJ; Donley, EL; Fontaine, BR; Kleinstreuer, NC; Knudsen, TB; Palmer, JA; Smith, AM; Weir-Hauptman, AM; West, PR, 2011
)
0.37
" The proportion of participants with adverse effects attributed to the treatment was also computed."( Nasal obstruction as a key symptom in allergic rhinitis: efficacy and safety of a medical device in children.
Bellussi, LM; Gregori, D; Lauriello, M; Passali, D; Passali, FM; Passali, GC,
)
0.13
"001), while only 9 patients suffered adverse effects (itch, burning sensation, dryness)."( Nasal obstruction as a key symptom in allergic rhinitis: efficacy and safety of a medical device in children.
Bellussi, LM; Gregori, D; Lauriello, M; Passali, D; Passali, FM; Passali, GC,
)
0.13
" Hepatotoxicity is a rare but serious side effect resulting from its use, particularly in young patients."( Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity.
Felker, D; Johnson, DE; Lynn, A; Wang, S, 2014
)
0.4
"Despite the availability of a number of pharmacological options, relief of allergic rhinitis (AR) symptoms, especially nasal obstruction, is often limited and local and systemic adverse reactions are not infrequent."( Efficacy and safety of a medical device in reducing nasal obstruction in allergic children.
Bellussi, LM; Cambi, J; Loglisci, M; Passali, D; Passali, FM, 2015
)
0.42
" Proportion of participants with adverse effects attributed to the treatment was computed."( Efficacy and safety of a medical device in reducing nasal obstruction in allergic children.
Bellussi, LM; Cambi, J; Loglisci, M; Passali, D; Passali, FM, 2015
)
0.42
"001), while only 1 patient suffered from moderate adverse effects."( Efficacy and safety of a medical device in reducing nasal obstruction in allergic children.
Bellussi, LM; Cambi, J; Loglisci, M; Passali, D; Passali, FM, 2015
)
0.42
" Toxic side effects of CIS treatment include nephrotoxicity, neurotoxicity, ototoxicity, myelosuppression and hepatotoxicity."( Protective effect of dexpanthenol on cisplatin induced nephrotoxicity in rats.
Büyük, E; Kaplan, M; Pınar, N; Seçinti, İE; Topaloğlu, M, 2022
)
0.72
" The Panel reviewed relevant data for these ingredients, and concluded that these 7 ingredients are safe in cosmetics in the present practices of use concentration described in this safety assessment."( Safety Assessment of Panthenol, Pantothenic Acid, and Derivatives as Used in Cosmetics.
Belsito, DV; Bergfeld, WF; Fiume, M; Heldreth, B; Hill, RA; Klaassen, CD; Liebler, DC; Marks, JG; Scott, LN; Shank, RC; Slaga, TJ; Snyder, PW, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" The plasma concentration curve for zinc orotate shows a faster distribution (alpha) and elimination phase (beta) after parenteral administration, and a slower absorption phase (Ka) after oral administration, when compared with that of the other two salts."( The bioavailability and pharmacokinetics of three zinc salts: zinc pantothenate, zinc sulfate and zinc orotate.
Andermann, G; Dietz, M, 1982
)
0.26
" These results demonstrate that RJX-P and RJX-B are bioequivalent relative to their pharmacodynamic effects on tissue SOD and ascorbic acid levels."( Non-clinical safety profile and pharmacodynamics of two formulations of the anti-sepsis drug candidate Rejuveinix (RJX).
Orhan, C; Ozercan, IH; Powell, J; Sahin, E; Sahin, K; Uckun, FM; Volk, M, 2021
)
0.62

Compound-Compound Interactions

ExcerptReferenceRelevance
"Analysis of the dynamics of changes in the end part of the ECG ventricular complex in 311 patients with rheumatic heart disease and stages IIA, IIB, and III circulatory insufficiency after treatment with preparations of digitalis and their combination with biologically active substances (orotic acid, vitamin B12, calcium pantothenate, ATP, methionine, inosi-F) is presented."( [Changes in the end part of the ECG ventricular complex under the effect of digitalis preparations and their combination with metabolic preparations].
Abbakumov, SA; Makolkin, VI; Masliuk, VI; Nedostup, AV; Popova, TA, 1977
)
0.26
"The purpose of the study was to assess whether it is possible to reduce the oxidative damage using antioxidant agents combined with hormone replacement therapy after menopause."( Effects of melatonin and dexpanthenol on antioxidant parameters when combined with estrogen treatment in ovariectomized rats.
Ay, A; Ay, AA; Dost, T; Kafkas, S; Turgut, H; Turgut, O, 2013
)
0.39

Bioavailability

The objective of the project was to determine the bioavailability of selected B vitamins (niacin, pantothenic acid and thiamin) to humans from wet and dry milled maize brans.

ExcerptReferenceRelevance
" This has place a greater emphasis on the bioavailability of nutrients in foods because the total intake of nutrients is generally closely linked with total caloric intake."( Bioavailability of vitamins.
Sauberlich, HE, 1985
)
0.27
"The objective of the project was to determine the bioavailability of selected B vitamins (niacin, pantothenic acid and thiamin) to humans from wet and dry milled maize brans which were coarsely or finely ground."( Niacin, thiamin, and pantothenic acid bioavailability to humans from maize bran as affected by milling and particle size.
Kies, C; Yu, BH, 1993
)
0.29
" The intestinal bioavailability of niacin and pantothenic acid was affected differently by the food administered."( Precaecal digestibility of niacin and pantothenic acid from different foods.
Kirchgessner, M; Roth-Maier, DA; Stangl, GI; Wauer, A, 2000
)
0.31
" The basal diet provided the 5 test vitamins at concentrations of total and estimated bioavailability equivalent to a minimum of 100 and 70%, respectively, of their estimated requirements (NRC, 1998) for 5- to 10-kg pigs."( Dietary B vitamin needs of strains of pigs with high and moderate lean growth.
Ewan, RC; Lutz, TR; Stahly, TS; Swenson, SG; Williams, NH, 2007
)
0.34
" Overall, this study demonstrated the bioavailability of antioxidants from a xanthone-rich mangosteen product and its in vivo antioxidant effects."( Bioavailability and antioxidant effects of a xanthone-rich Mangosteen (Garcinia mangostana) product in humans.
Ji, H; Kondo, M; Kou, Y; Ou, B; Zhang, L, 2009
)
0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Taking into account the discovery of new functions of CoA (redox-dependent processes of CoAlation of proteins, possible association of oxidative stress and deficiency of Pan (CoA) in neurodegenerative pathology), it seems promising to study bioavailability and biotransformation of Pan derivatives, in particular of D-panthenol, 4'-phospho-pantetheine, its acylated derivatives, and compositions with redox pharmacological compounds, are promising for their potential use as etiopathogenetic agents."( Brain CoA and Acetyl CoA Metabolism in Mechanisms of Neurodegeneration.
Kanunnikova, NP; Moiseenok, AG, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" The recommended dosage is 20 drops three times daily, to be taken for 5 to 10 years following cancer surgery."( [GELUM oral-rd: blood pH regulator and oxygen activator. Documentation No.27].
Deplazes, G; Hauser, SP, 1990
)
0.28
" The dose-response curve for GABA-induced Cl- conductance was sigmoidal with the GABA concentration producing a half-maximum response (4."( Interactions of gamma-aminobutyric acid (GABA), pentobarbital, and homopantothenic acid (HOPA) on internally perfused frog sensory neurons.
Akaike, N; Oomura, Y, 1985
)
0.27
" The dosage of MV-GABA which caused locomotor hypoactivity produced an impairment of the rotarod performance."( [Behavioral pharmacological action of Ca-4-(3,5-dihydroxy-3-methylpenthylamido) butyrate (mevalonic GABA, MV-GABA)].
Kameyama, T; Nabeshima, T; Noda, Y, 1987
)
0.27
" The dose-response curve of ifenprodil tartrate was shifted to the left by pre-incubation in calcium hopantenate."( A possible mechanism on the potentiating vascular effect of coadministration of ifenprodil tartrate and calcium hopantenate: a study in the internal carotid artery.
Honda, H; Irino, O; Iwata, T; Izumisawa, M; Matsuda, H; Shibuya, T; Shimura, H; Tsuji, H; Watanabe, Y, 1988
)
0.27
" The protein synthesis and secretion were determined by dosage in the cells and in the culture medium."( Effects of pantothenic acid on fibroblastic cell cultures.
Didier, E; Grenier, JF; Lacroix, B, 1988
)
0.27
" In the dilution and dosage unit based on the continuous-flow principle, vitamin samples were diluted to two different dose levels at a rate of 40 per hr, mixed with the inoculated test broth, and dispensed into culture tubes."( Semiautomated method for microbiological vitamin assays.
Behagel, HA; Berg, TM, 1972
)
0.25
", of dosage equivalent to 150 mg/kg body wt of phosphopantothenate)."( Hypolipidemic effect of pantothenic acid derivatives in mice with hypothalamic obesity induced by aurothioglucose.
Buko, V; Naruta, E, 2001
)
0.31
" Pantogam was administered in dosage 750-3000 mg per day along with traditional and atypical neuroleptics."( [Pantogam in daily psychiatric practice].
Bogdan, MN; Kontsevoĭ, VA; Riakhovskiĭ, VV; Rotshteĭn, VG, 2007
)
0.34
"For full compatibility groups (age, ASA status and anthropometric data, equal operation duration and the equipotential drug dosage adjustment is revealed, that in group of propofol-fentanyl TIVA in the early postoperative period in school age children postoperative cognitive dysfunction (POCD) is developing, which in case of absence of the corresponding correction is maintained after 1 month after operation (at least) in 80% of cases."( [Correction of early cognitive disorders in school-age children operated under total intravenous anaesthesia].
Gus'kov, IE; Lobov, MA; Lugovoĭ, AV; Miatchin, PS; Ovezov, AM; Panteleeva, MV,
)
0.13
" This adverse effect does not display normal dose-response curves and can be lethal in children."( Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity.
Felker, D; Johnson, DE; Lynn, A; Wang, S, 2014
)
0.4
" However, before these agents are recommended for general use, large multicenter trials should be done exploring not only efficacy but also dose-response relationships and side effects."( Novel preoperative pharmacologic methods of preventing postoperative sore throat due to tracheal intubation.
Austin, PN; Kalil, DM; Silvestro, LS, 2014
)
0.4
" Second, in vivo effect of different dosage patterns and concentrations in the development of hepatic metastasis was analyzed by intra-splenic inoculation of C26 colon carcinoma cells in Balb/c mice."( Ocoxin® oral solution slows down tumor growth in an experimental model of colorectal cancer metastasis to the liver in Balb/c mice.
Arteta, B; Benedicto, A; Hernandez-Unzueta, I; Márquez, J; Mena, J; Olaso, E; Sanz, E, 2016
)
0.43
" Consistent with the difference in whole blood half-life, fosmetpantotenate dosed orally was found in the brains of the monkey (striatal dialysate) but was absent in mice."( Fosmetpantotenate (RE-024), a phosphopantothenate replacement therapy for pantothenate kinase-associated neurodegeneration: Mechanism of action and efficacy in nonclinical models.
Beconi, MG; Di Marco, A; Elbaum, D; Harper, S; Lyons, KA; Monteagudo, E; Quinton, MS; Vaino, A, 2018
)
0.48
"Key words: silver citrate arginine dexpanthenol intramammary dosage form stability."( Development of the composition of intramammary combined preparation based on silver citrate for veterinary use.
Almakayeva, L; Nehoda, T; Polova, Z,
)
0.13
" The validated method therefore can be adapted for quality control procedures of the drugs in pharmaceutical dosage forms and their stability studies."( Simultaneous Determination of Dexpanthenol, Lidocaine Hydrochloride, Mepyramine Maleate and their Related Substances by a RP-HPLC Method in Topical Dosage Forms.
Capan, Y; Doganay, A; Gundogdu, SO; Koksel, B, 2018
)
0.48
" Pantogam (syrup 100 mg/ml) or placebo were prescribed orally 15-30 minutes after feeding, twice a day, in a daily dosage of 30-50 mg/kg body weight."( [Pharmacotherapy of psychomotor developmental delay in 6-12 months preterm infants with hypoxic-ischemic encephalopathy (the double-blind comparative multicenter placebo-controlled study)].
Davydova, LA; Gaynetdinova, DD; Guzeva, VI; Romanova, TA; Zavadenko, AN; Zavadenko, NN, 2019
)
0.51
" Enhanced supply of another precursor, β-alanine was achieved by codon optimization and dosing of the limiting L-asparate-1-decarboxylase (ADC)."( Engineering precursor and co-factor supply to enhance D-pantothenic acid production in Bacillus megaterium.
Allampalli, SSP; Nehru, G; Sivaprakasam, S; Tadi, SRR, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antidote to curare poisoningA role borne by a molecule that acts to counteract or neutralize the deleterious effects of curare.
human blood serum metaboliteAny metabolite (endogenous or exogenous) found in human blood serum samples.
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pantothenic acidA member of the class of pantothenic acids that is an amide formed from pantoic acid and beta-alanine.
vitamin B5Any member of a group of vitamers that belong to the chemical structural class called pantothenic acids that exhibit biological activity against vitamin B5 deficiency. Deficiency of vitamin B5 is rare due to its widespread distribution in whole grain cereals, legumes and meat. Symptoms associated with vitamin B5 deficiency are difficult to asses since they are subtle and resemble those of other B vitamin deficiencies. The vitamers include (R)-pantothenic acid and its ionized and salt forms.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
pantothenate and coenzyme A biosynthesis022
Biochemical pathways: part I0466

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
EWS/FLI fusion proteinHomo sapiens (human)Potency28.70270.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency25.11890.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Type II pantothenate kinaseStaphylococcus aureus subsp. aureus MSSA476Km19.00001.50001.50001.5000AID1419201
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (49)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID629625Binding affinity to hen egg white lysozyme assessed as quenching rate constant at 310 K by Stern-Volmer plot analysis2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Comparative studies on interactions of baicalein, baicalin and scutellarin with lysozyme.
AID1419204Substrate activity at Pseudomonas aeruginosa PanK3 expressed in Escherichia coli BL21(DE3) cells assessed as Km in presence of ATP/NADH by pyruvate kinase/lactate dehydrogenase enzyme coupled assay2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Probing the ligand preferences of the three types of bacterial pantothenate kinase.
AID1419205Substrate activity at Pseudomonas aeruginosa PanK3 expressed in Escherichia coli BL21(DE3) cells assessed as Kcat in presence of ATP/NADH by pyruvate kinase/lactate dehydrogenase enzyme coupled assay2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Probing the ligand preferences of the three types of bacterial pantothenate kinase.
AID1419202Substrate activity at N-terminal His6-tagged Staphylococcus aureus PanK2 expressed in Escherichia coli BL21(DE3) cells assessed as Kcat in presence of ATP/NADH by pyruvate kinase/lactate dehydrogenase enzyme coupled assay2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Probing the ligand preferences of the three types of bacterial pantothenate kinase.
AID1419199Substrate activity at N-terminal His6-tagged Escherichia coli PanK1 expressed in Escherichia coli BL21(DE3) cells assessed as Kcat in presence of ATP/NADH by pyruvate kinase/lactate dehydrogenase enzyme coupled assay2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Probing the ligand preferences of the three types of bacterial pantothenate kinase.
AID629626Binding affinity to hen egg white lysozyme assessed as effective quenching constant at 298 K by Lineweaver-Burk plot analysis2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Comparative studies on interactions of baicalein, baicalin and scutellarin with lysozyme.
AID1419200Substrate activity at N-terminal His6-tagged Escherichia coli PanK1 expressed in Escherichia coli BL21(DE3) cells assessed as ratio of Kcat to Km in presence of ATP/NADH by pyruvate kinase/lactate dehydrogenase enzyme coupled assay2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Probing the ligand preferences of the three types of bacterial pantothenate kinase.
AID1419198Substrate activity at N-terminal His6-tagged Escherichia coli PanK1 expressed in Escherichia coli BL21(DE3) cells assessed as Km in presence of ATP/NADH by pyruvate kinase/lactate dehydrogenase enzyme coupled assay2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Probing the ligand preferences of the three types of bacterial pantothenate kinase.
AID629623Binding affinity to hen egg white lysozyme assessed as Stem-Volmer dynamic quenching constant at 310 K by Stern-Volmer plot analysis2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Comparative studies on interactions of baicalein, baicalin and scutellarin with lysozyme.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID603957Octanol-water partition coefficient, log P of the compound2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
QSPR modeling of octanol/water partition coefficient for vitamins by optimal descriptors calculated with SMILES.
AID629622Binding affinity to hen egg white lysozyme assessed as Stem-Volmer dynamic quenching constant at 298 K by Stern-Volmer plot analysis2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Comparative studies on interactions of baicalein, baicalin and scutellarin with lysozyme.
AID1419203Substrate activity at N-terminal His6-tagged Staphylococcus aureus PanK2 expressed in Escherichia coli BL21(DE3) cells assessed as ratio of Kcat to Km in presence of ATP/NADH by pyruvate kinase/lactate dehydrogenase enzyme coupled assay2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Probing the ligand preferences of the three types of bacterial pantothenate kinase.
AID1419206Substrate activity at Pseudomonas aeruginosa PanK3 expressed in Escherichia coli BL21(DE3) cells assessed as ratio of Kcat to Km in presence of ATP/NADH by pyruvate kinase/lactate dehydrogenase enzyme coupled assay2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Probing the ligand preferences of the three types of bacterial pantothenate kinase.
AID1419201Substrate activity at N-terminal His6-tagged Staphylococcus aureus PanK2 expressed in Escherichia coli BL21(DE3) cells assessed as Km in presence of ATP/NADH by pyruvate kinase/lactate dehydrogenase enzyme coupled assay2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Probing the ligand preferences of the three types of bacterial pantothenate kinase.
AID629624Binding affinity to hen egg white lysozyme assessed as quenching rate constant at 298 K by Stern-Volmer plot analysis2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Comparative studies on interactions of baicalein, baicalin and scutellarin with lysozyme.
AID629627Binding affinity to hen egg white lysozyme assessed as effective quenching constant at 310 K by Lineweaver-Burk plot analysis2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Comparative studies on interactions of baicalein, baicalin and scutellarin with lysozyme.
AID681021TP_TRANSPORTER: inhibition of PAH uptake (PAH: 20 uM, Pantothenic acid: 1000 uM) in OAT-expressing COS-7 cells1999The Journal of biological chemistry, Jan-15, Volume: 274, Issue:3
Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,712)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901916 (70.65)18.7374
1990's147 (5.42)18.2507
2000's218 (8.04)29.6817
2010's309 (11.39)24.3611
2020's122 (4.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials112 (3.70%)5.53%
Reviews140 (4.63%)6.00%
Case Studies61 (2.02%)4.05%
Observational1 (0.03%)0.25%
Other2,713 (89.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Clinical Study of Vitamin B5 in Adjuvant Treatment of Inflammatory Bowel Disease [NCT05701501]100 participants (Anticipated)Interventional2023-02-01Recruiting
Multicenter, Two-phase Exploratory Clinical Trial to Examine Efficacy and Safety After Open-label Topical Administration of a Medical Device (Bepanthen Itch Relief Cream) for Treatment of Acute Flare-ups Followed by Topical Administration of a New Cosmeti [NCT02615561]136 participants (Actual)Interventional2015-12-15Completed
Evaluation of the Moisturizing Effect of Bepanthen Burn Relief Foam Spray New Formula Versus Bepanthen Burn Relief Foam Spray (Current Formula). Equivalence Trial. Intra-individual Design. [NCT00839280]Phase 219 participants (Actual)Interventional2007-08-31Completed
Evaluation of the Effect of Bepanthen Burn Relief Foam Spray New Formula on a Thermic Erythema. Equivalence Trial. Intra-individual Design. [NCT00839462]Phase 255 participants (Actual)Interventional2007-09-30Completed
Personalized Non-invasive Neuromodulation by rTMS for Chronic and Treatment Resistant Catatonia - A Proof of Concept Study [NCT03116425]17 participants (Actual)Interventional2017-04-24Active, not recruiting
Study of the Efficacy of Topical Application of Royal Jelly and Panthenol (PedyPhar® Ointment) on the Diabetic Foot Ulcers, An Open Label, Randomized, Non-placebo-controlled Study [NCT01531517]Phase 347 participants (Actual)Interventional2011-07-31Terminated(stopped due to inability to recruit patients)
Study Phase III, Randomized, Double-dummy, Placebo Controlled, Single-center, of Regarding the Non-inferiority of the Medication BL3000, When Compared to Pantogar® Treatment of Telogen Effluvium in Women. [NCT04880889]Phase 3326 participants (Anticipated)Interventional2023-01-01Not yet recruiting
Phase I Clinical Study, to Evaluate the Safety and Tolerability of the Ophthalmic Gel PRO-167 Versus Corneregel®, on the Ocular Surface of Ophthalmological and Clinically Healthy Subjects. [NCT03520348]Phase 124 participants (Actual)Interventional2017-10-04Completed
An Evaluation of the Safety and Efficacy of a Hydrocolloid Bandage on Pimples [NCT05012735]Phase 141 participants (Actual)Interventional2021-07-19Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT03520348 (10) [back to overview]Breakup Time (BUT)
NCT03520348 (10) [back to overview]Chemosis
NCT03520348 (10) [back to overview]Goblet Cell Density (GCD)
NCT03520348 (10) [back to overview]Intraocular Pressure (IOP)
NCT03520348 (10) [back to overview]Presence of Adverse Events (EAS)
NCT03520348 (10) [back to overview]Conjunctival Hyperemia (CH)
NCT03520348 (10) [back to overview]Epithelial Defects (ED)
NCT03520348 (10) [back to overview]Foreign Body Sensation (FBS)
NCT03520348 (10) [back to overview]Ocular Burning (OB)
NCT03520348 (10) [back to overview]Ocular Pruritus (P)

Breakup Time (BUT)

breakup time lacrimal film is a continuous variable that will be measured in seconds, evaluating the time it takes to break it, is done by direct counting and the normality range greater than 10 seconds. (NCT03520348)
Timeframe: will be evaluated at the end of the treatment at the final visit (day 11)

Interventionseconds (Mean)
PRO-1678.92
Corneregel®7.75

[back to top]

Chemosis

The chemosis will be evaluated, as a nominal variable, by direct observation and it will be staged as present and absent, where the normality is that said variable is absent. (NCT03520348)
Timeframe: will be evaluated at the end of the treatment at the final visit (day 11)

Interventioncases (Number)
PRO-1670
Corneregel®0

[back to top]

Goblet Cell Density (GCD)

the cells will be measured per square millimeter, it is a continuous variable taken by means of cytology per impression, the normal value is higher than 500 cells per square millimeter (NCT03520348)
Timeframe: will be evaluated at the end of the treatment at the final visit (day 11)

Interventioncells/mm^2 (Mean)
PRO-167444
Corneregel®440

[back to top]

Intraocular Pressure (IOP)

the intraocular pressure will be evaluated by means of the Goldman applanation tonometry whose unit of measurement is millimeters of mercury (mmHg), it is a continuous variable and its normality range is between 11 - 21 mmHg (NCT03520348)
Timeframe: will be evaluated at the end of the treatment at the final visit (day 11)

InterventionmmHg (Mean)
PRO-16713.14
Corneregel®13.56

[back to top]

Presence of Adverse Events (EAS)

the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent. (NCT03520348)
Timeframe: during the 11 days of evaluation, including the safety call (day 13).

Interventioncases (Number)
PRO-1677
Corneregel®6

[back to top]

Conjunctival Hyperemia (CH)

Conjunctival hyperemia will be evaluated as an ordinal variable, by direct observation and staged using the Efron scale as Normal / Very Light / Mild / Moderate / Severe. Based on this scale, the normal and mild stages are considered without pathologies or normal. Mild, moderate and severe are considered pathological. (NCT03520348)
Timeframe: will be evaluated at the end of the treatment at the final visit (day 11)

,
Interventionpercentage of participants (Number)
NormalVery mildMild
Corneregel®8.366.725
PRO-16716.766.616.7

[back to top]

Epithelial Defects (ED)

The epithelial defects will be evaluated by means of two stains, green lissamine, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects. (NCT03520348)
Timeframe: will be evaluated at the end of the treatment at the final visit (day 11)

,
Interventioncases (Number)
grade 0grade Igrade II
Corneregel®831
PRO-167840

[back to top]

Foreign Body Sensation (FBS)

"Foreign body sensation is a nominal variable that will be evaluated by direct questioning to the research subject, then it will be staged according to the following scale:~Severity: Absent, very mild, mild, moderate and severe, where the normality of severity is absent.~Frequency: At all times, almost at all times, 50% of the time, almost in no time, at any time. where the normality of the frequency is in no time." (NCT03520348)
Timeframe: will be evaluated at the end of the treatment at the final visit (day 11)

,
Interventionpercentage of participants (Number)
AbsentVery mildMildModerate
Corneregel®91.78.300
PRO-16779.220.800

[back to top]

Ocular Burning (OB)

ocular burning is a nominal variable that will be evaluated by direct questioning to the research subject, then it will be staged according to the following scale: Severity: Absent, very mild, mild, moderate and severe, where the normality of severity is absent.Frequency: At all times, almost at all times, 50% of the time, almost in no time, at any time. where the normality of the frequency is in no time. (NCT03520348)
Timeframe: will be evaluated at the end of the treatment at the final visit (day 11)

,
Interventionpercentage of participants (Number)
AbsentmildmoderateSevere
Corneregel®75168.30
PRO-16766.729.24.20

[back to top]

Ocular Pruritus (P)

"Ocular pruritus is a nominal variable that will be evaluated by direct questioning to the research subject, then it will be staged according to the following scale:~Severity: Absent, very mild, mild, moderate and severe, where the normality of severity is absent.~Frequency: At all times, almost at all times, 50% of the time, almost in no time, at any time. where the normality of the frequency is in no time." (NCT03520348)
Timeframe: will be evaluated at the end of the treatment at the final visit (day 11)

,
Interventionpercentage of participants (Number)
AbsentVery mildMildModerate
Corneregel®66.716.716.70
PRO-16741.7508.30

[back to top]